| ABTI Stock | | | USD 0 0.0001 2.44% |
Insider
Hunter Land is VP Director of Alterola Biotech
| Age | 38 |
| Phone | 44 1516 019 477 |
| Web | https://alterola-abti.com |
Alterola Biotech Management Efficiency
The company has return on total asset
(ROA) of
(0.6669) % which means that it has lost $0.6669 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.2729) %, meaning that it created substantial loss on money invested by shareholders. Alterola Biotech's management efficiency ratios could be used to measure how well Alterola Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Alterola Biotech currently holds 251.18
K in liabilities with Debt to Equity
(D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Alterola Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Alterola Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Alterola Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alterola Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alterola to invest in growth at high rates of return. When we think about Alterola Biotech's use of debt, we should always consider it together with cash and equity.
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products production of active pharmaceutical ingredients and food-grade ingredients and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech is traded on OTC Exchange in the United States. Alterola Biotech [ABTI] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Alterola Biotech Leadership Team
Elected by the shareholders, the Alterola Biotech's board of directors comprises two types of representatives: Alterola Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alterola. The board's role is to monitor Alterola Biotech's management team and ensure that shareholders' interests are well served. Alterola Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alterola Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alterola Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Alterola Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Alterola Pink Sheet
Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.